Medicare Requirements for Oxygen Therapy Coverage
Medicare covers home oxygen therapy for patients with severe hypoxemia who meet specific arterial blood gas criteria: PaO2 ≤55 mmHg (7.3 kPa) or oxygen saturation ≤88%, or PaO2 56-59 mmHg (7.4-7.8 kPa) with evidence of hypoxic organ dysfunction such as cor pulmonale, peripheral edema, polycythemia (hematocrit ≥55%), or pulmonary hypertension. 1, 2
Core Medicare Coverage Criteria
Primary Qualification Thresholds
Medicare requires documentation of hypoxemia while the patient is in a stable clinical state, not during an acute exacerbation 2:
- PaO2 ≤55 mmHg (7.3 kPa) OR SaO2 ≤88% qualifies automatically for coverage 1, 2
- PaO2 56-59 mmHg (7.4-7.8 kPa) OR SaO2 89% requires additional evidence of hypoxic organ dysfunction 2
Evidence of Hypoxic Organ Dysfunction
When arterial oxygen levels fall in the borderline range (PaO2 56-59 mmHg), Medicare requires documentation of at least one of the following 3, 2:
- Peripheral edema suggesting cor pulmonale 3
- Polycythemia with hematocrit ≥55% 3
- Pulmonary hypertension documented by echocardiography or right heart catheterization 3
- P pulmonale on electrocardiogram (P wave >3 mm in standard leads II, III, or aVF) 2
Medical Review Requirements
Medical review by the insurance carrier is mandatory when prescribing oxygen for less severe hypoxemia (PaO2 ≥60 mmHg or SaO2 ≥90%), such as for exercise-induced or nocturnal desaturation only 2. These cases require detailed documentation justifying the medical necessity.
Documentation Requirements
Certificate of Medical Necessity (Form HCFA-484)
The physician or an employee of the physician must complete the Certificate of Medical Necessity (form HCFA-484); failure to do so prevents reimbursement to the oxygen supplier 1. This form must include 1, 2:
- Arterial blood gas results or oxygen saturation measurements obtained while patient is at rest, awake, and breathing room air 2
- Confirmation that measurements were taken when patient was clinically stable (not during acute exacerbation) 2
- Specific oxygen flow rate prescribed 2
- Duration of use (continuous, during sleep, during exercise) 2
- Type of equipment prescribed 2
Testing Requirements
Arterial blood gas measurement is the gold standard for Medicare documentation, though pulse oximetry may be acceptable if arterial blood gases cannot be obtained 2. Testing must demonstrate 2:
- Patient is in stable clinical condition (typically at least 30 days after hospital discharge for acute exacerbation) 1
- Patient is on optimal medical therapy for underlying condition 1
- Measurements taken at rest while breathing room air 2
Equipment Prescription Specifications
Stationary vs. Portable Systems
Portable oxygen equipment should be provided in addition to stationary equipment when patients have resting hypoxemia requiring continuous therapy 2. The prescription must specify 2:
- Oxygen concentrator with small portable cylinder system fulfills most needs for continuous oxygen users 2
- Portable equipment alone is sufficient only when hypoxemia occurs exclusively during exercise with normal oxygenation at rest 2
- Liquid oxygen systems may be prescribed for highly active ambulatory patients 2
Flow Rate Specifications
The prescription must include explicit instructions for 2:
- Specific liter flow rate (e.g., 2 L/min, not "as needed") 2
- Duration of use (continuous 24 hours/day, during sleep only, during exertion) 2
- Adjustments for different activities if applicable 2
Disease-Specific Considerations
COPD Patients
For COPD patients, long-term oxygen therapy (LTOT) should be ordered when resting PaO2 ≤7.3 kPa (55 mmHg) or when PaO2 ≤8 kPa (60 mmHg) with evidence of peripheral edema, polycythemia (hematocrit ≥55%), or pulmonary hypertension 3. Patients with resting hypercapnia who meet other LTOT criteria should still receive oxygen therapy 3.
Interstitial Lung Disease and Pulmonary Fibrosis
LTOT should be ordered for patients with ILD or pulmonary fibrosis with resting PaO2 ≤7.3 kPa (55 mmHg), or PaO2 ≤8 kPa (60 mmHg) in the presence of peripheral edema or pulmonary hypertension 3. These recommendations are extrapolated from COPD evidence as no randomized trials exist for ILD populations 3.
Cystic Fibrosis
LTOT should be ordered for CF patients with resting PaO2 ≤7.3 kPa (55 mmHg), or PaO2 ≤8 kPa (60 mmHg) with peripheral edema, polycythemia (hematocrit ≥55%), or pulmonary hypertension 3.
Pulmonary Hypertension
LTOT should be ordered for patients with pulmonary hypertension, including idiopathic pulmonary hypertension, when PaO2 ≤8 kPa (60 mmHg) 3. The goal is tissue oxygenation and prevention of complications rather than proven survival benefit 3.
Common Pitfalls and How to Avoid Them
Testing During Acute Illness
Never obtain qualifying arterial blood gases during an acute exacerbation or hospitalization for acute illness 2. Patients should be clinically stable, typically requiring reassessment 30-60 days after hospital discharge before oxygen can be prescribed for long-term use 1. Testing during acute illness will result in denial of coverage.
Incomplete Documentation
Ensure the Certificate of Medical Necessity is completed in its entirety by the physician or physician's employee 1. Missing information, particularly arterial blood gas values, clinical stability confirmation, or specific equipment/flow rate prescriptions, will result in claim denial 1, 2.
Inadequate Equipment Prescription
Prescribe both stationary and portable systems for patients requiring continuous oxygen 2. Prescribing only stationary equipment for patients who need continuous therapy limits their mobility and quality of life unnecessarily 2.
Failure to Reassess
Patients started on oxygen during hospitalization for acute exacerbation may improve and no longer meet criteria once stable 4. Reassessment 30-60 days after discharge is essential, and oxygen should be discontinued if criteria are no longer met, as there is no proven survival benefit for mild hypoxemia 4.